Related Experiment Video
Updated: Dec 27, 2025
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.8K
Locally Advanced, Unresectable Non-Small Cell Lung Cancer
Sonam Puri1, Andreas Saltos2, Bradford Perez2
1Division of Medical Oncology, The University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA.
Current Oncology Reports
|March 7, 2020
Summary
Immunotherapy combined with chemoradiation is revolutionizing unresectable non-small cell lung cancer (NSCLC) treatment. Ongoing trials explore novel strategies to improve outcomes and reduce toxicities for locally advanced NSCLC.
Area of Science:
- Oncology
- Pulmonology
- Immunotherapy
Background:
- Locally advanced, unresectable non-small cell lung cancer (NSCLC) treatment traditionally relies on concurrent chemoradiation.
- This approach, while curative in intent, is linked to significant toxicities and a high risk of disease relapse.
Purpose of the Study:
- To review current standard practices for managing locally advanced, unresectable NSCLC.
- To examine ongoing studies evaluating novel treatment strategies, including immunotherapy and targeted therapies.
Main Methods:
- Review of current clinical practices and ongoing research in NSCLC management.
- Analysis of immunotherapy integration with standard chemoradiation protocols.
Main Results:
- The incorporation of immunotherapy, such as durvalumab (a PD-L1 inhibitor), has significantly advanced treatment for unresectable stage III NSCLC.
- Durvalumab consolidation therapy post-chemoradiation represents a major improvement.
Conclusions:
- Immunotherapy integration marks a significant advancement in treating unresectable, locally advanced NSCLC.
- Ongoing clinical trials are crucial for optimizing immunotherapy sequencing and biomarker-driven strategies to enhance efficacy and minimize toxicity.
